Track the 에스케이바이오팜 share price and the full insider trade history of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 에스케이바이오팜 has published 33 reports. Market capitalisation: €5,904.8bn. The latest transaction was filed on 1 April 2026 (Sale). Among the most active insiders: 조형래. Every trade is accessible without an account.
33
Insider Decl.
n/a
Thresholds
n/a
7 ops.
Buy Volume
n/a
2 ops.
Sell Volume
9Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,329 of 28,199 companies
67.4
score / 100
Value
41
Quality
93
FCF yld2.5%
Earn yld4.5%
EV/EBITDA33.9x
ROE44%
Gross mgn94%
Net mgn38%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
SK Biopharmaceuticals is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments for neurological and psychiatric disorders.